Estados Unidos · Bolsa y Finanzas · The Motley Fool

AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.

Publicado por The Motley Fool · Estados Unidos hace 7 h

Earlier this week, the U.S. Food and Drug Administration (FDA) approved AbbVie 's ( ABBV +1.11%) Juvmo (tavapadon). This is a once-daily pill for adults with Parkinson's disease…

Leer el artículo completo en The Motley Fool Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)

AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.

También te puede interesar

Top Performing Stocks

Ramp's Broadway musical was the worst show I've ever seen. I'm still glad it exists.

10 U.S. cities where it takes the biggest paycheck to buy a home

Trump Says Economy Has ‘Public Relations’ Problem Amid High Prices and Slow Hiring

America’s data center fight is a preview of what's to come for the rest of the world

‘Don’t Screw Up Your Rollover’: Before rolling over your 401(k), check withdrawal options, tax breaks you could be giving up

AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.

Compartir

También te puede interesar

Top Performing Stocks

Ramp's Broadway musical was the worst show I've ever seen. I'm still glad it exists.

10 U.S. cities where it takes the biggest paycheck to buy a home

Trump Says Economy Has ‘Public Relations’ Problem Amid High Prices and Slow Hiring

America’s data center fight is a preview of what's to come for the rest of the world

‘Don’t Screw Up Your Rollover’: Before rolling over your 401(k), check withdrawal options, tax breaks you could be giving up